Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
The aim is to create new genomics solutions that could combat cancer and advance market access
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
A veteran in cell therapy and oncology commercialisation
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Advances deployment of mRNA technology across vaccines and therapeutics development
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Subscribe To Our Newsletter & Stay Updated
